Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Adverse Event Analysis By FDA Will Project Incidence Rates

Executive Summary

FDA plans to use hospital use data to project use among the in-patient pediatric population to determine incidence rates for adverse event reports mandated by the Best Pharmaceuticals for Children Act
Advertisement

Related Content

Zyrtec Mix-Ups With Zantac Cited In FDA Pediatric Adverse Events Review
Zyrtec Mix-Ups With Zantac Cited In FDA Pediatric Adverse Events Review
Lipitor, Zocor Pediatric Safety Surveillance Needs More Time, FDA Cmte. Says
Lipitor, Zocor Pediatric Safety Surveillance Needs More Time, FDA Cmte. Says
BPCA adverse event reporting
BPCA adverse event reporting
Barr Expects Metformin Launch By Early February; Pediatric Bill Signed
Barr Expects Metformin Launch By Early February; Pediatric Bill Signed
Advertisement
UsernamePublicRestriction

Register

PS041537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel